AstraZeneca, GlaxoSmithKline plc, Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) are Dominating the Global Bronchiectasis Market in 2020

Global Bronchiectasis Market is expected to grow with the CAGR of 6.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-bronchiectasis-market

Global bronchiectasis market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario. 

The major players dealing in global bronchiectasis market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In March 2016, Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) launched the generic equivalent of Pulmicort Repsules (budesonide inhalation suspension) in the U.S. The product launched is an inhaled corticosteroid indicated for treatment of respiratory problems and has been proved efficacious for control of inflammatory symptoms and swelling of lungs. This initiative helped the company to boost up the overall product portfolio and to earn more revenue.

AstraZeneca is the dominating player in global bronchiectasis market. The other key players existing in the market includes Abbott, HERSILL, Home Oxygen Company, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos S.A., Horizon Therapeutics plc, Johnson & Johnson, Inc. Trudell Medical International, GlaxoSmithKline plc., Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis AG, Teva Pharmaceutical USA Inc.(A Subsidiary of Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Sunovion Pharmaceuticals Inc. (A Subsidiary of Sumitomo Dainippon Pharma Co., Ltd.), Viatris Inc., Covis Pharma, Zydus Pharmaceuticals, Inc. (A subsidiary of Zydus Cadila), Cipla Inc. Electromed, Inc., among others.

Bronchiectasis MarketAstraZeneca

AstraZeneca was founded in 1999 and is headquartered in Cambridge, U.K. The company is focused on the manufacturing of innovative medicines which are used by millions of patients worldwide. The company has several categories such as Cardiovascular, Renal and Metabolic Diseases, Oncology, Infection and Vaccines, Neuroscience, Respiratory, Gastrointestinal. The market focused category is Respiratory. The company has presence across Africa, Americas, Asia-Pacific, Europe, Middle East and Africa. The company also generates its revenue from various subsidiaries such as AstraZeneca India Pvt. Limited (India), AstraZeneca Czech Republic s.r.o. (Czech Republic), AstraZeneca B.V. (the Netherlands), AstraZeneca GmbH (Germany), AstraZeneca AUSTRALIA (Australia) among others.

For instance,

  • In June 2019, AstraZeneca received approval for Breztri Aerosphere (PT010) in Japan for treatment of COPD. Breztri Aerosphere comprises of budesonide/glycopyrronium/ formoterol fumarate and proved as new treatment choice among the people suffering from lung inflammation and other chronic obstructive disease. This approval helped the company to earn constant sales by expanding its product sales across several regions of world.

GlaxoSmithKline plc

GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, United Kingdom. The company is focused to become one of the best company in the field of innovation, development of drugs and vaccines that will be beneficial to both patient and consumers. The company has several product categories such as Prescription Medicines, Vaccines, Consumer Healthcare Products, ViiV Healthcare, and Stiefel Dermatology. The market focused category is Prescription Medicines. The company has presence across Africa, Asia & Middle East, Australasia, Europe, North America, South & Central America. The company also generates its revenue from various subsidiaries such as GlaxoSmithKline Pharmaceuticals Ltd (Mumbai), Tesaro (Waltham, Massachusetts, United States),GlaxoSmithKline Pakistan (Karachi, Pakistan), Stiefel Laboratories (North Carolina, United States), Allen & Hanburys (Ware, United Kingdom), among others.

For instance,

  • In September 2020, GlaxoSmithKline plc received approval for Trelegy Ellipta from U.S FDA for treatment of asthma and other COPD disease in the U.S. This approval paved the way for product approval and allowed the company to expand its portfolio of innovative medicines for patients suffering from respiratory diseases.

Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)

Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) is headquartered in New Jersey, U.S. The company is focused on the development and production of affordable, high-quality generic drugs, innovative specialty pharmaceuticals and active pharmaceutical ingredients. The company has several product categories such as Generic Medicines, Specialty Medicines, and Biopharmaceuticals. The market focused category are Generic Medicines, Specialty Medicines. The company has presence across North America.

For instance,

  • In July 2020, Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) launched ProAir Digihaler (albuterol sulfate 117 mcg) inhalation powder, which is the first digital inhaler indicated for the treatment of respiratory problems in pediatric patients. This product launch helps the patients to control their drug dosage ad to manage their health conditions. This product launch boosted the company’s product portfolio and helped it to establish its footprint in the bronchiectasis market.